Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:GNFT NASDAQ:HRTX NYSEAMERICAN:MAIA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.11-3.3%$7.28$3.54▼$8.90$193.38M0.8148,143 shs135,482 shsGNFTGENFIT$4.20+0.3%$3.95$2.55▼$6.42$209.51M1.162,554 shs3,470 shsHRTXHeron Therapeutics$1.26-1.6%$1.63$1.04▼$2.68$234.64M1.221.46 million shs1.40 million shsMAIAMAIA Biotechnology$1.68-1.2%$1.63$1.40▼$3.48$56.09M0.01419,650 shs605,975 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%+1.43%-2.07%+4.87%+48.43%GNFTGENFIT0.00%+7.17%+2.21%+2.46%+0.74%HRTXHeron Therapeutics0.00%-3.82%-6.67%-34.72%-30.39%MAIAMAIA Biotechnology0.00%+9.09%+7.69%-2.33%-47.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.11-3.3%$7.28$3.54▼$8.90$193.38M0.8148,143 shs135,482 shsGNFTGENFIT$4.20+0.3%$3.95$2.55▼$6.42$209.51M1.162,554 shs3,470 shsHRTXHeron Therapeutics$1.26-1.6%$1.63$1.04▼$2.68$234.64M1.221.46 million shs1.40 million shsMAIAMAIA Biotechnology$1.68-1.2%$1.63$1.40▼$3.48$56.09M0.01419,650 shs605,975 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%+1.43%-2.07%+4.87%+48.43%GNFTGENFIT0.00%+7.17%+2.21%+2.46%+0.74%HRTXHeron Therapeutics0.00%-3.82%-6.67%-34.72%-30.39%MAIAMAIA Biotechnology0.00%+9.09%+7.69%-2.33%-47.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 2.50Moderate Buy$12.1771.12% UpsideGNFTGENFIT 3.00Buy$9.00114.23% UpsideHRTXHeron Therapeutics 2.33Hold$4.50257.14% UpsideMAIAMAIA Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MAIA, GNFT, HRTX, and DERM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025DERMJourney MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.008/19/2025GNFTGENFITHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.008/15/2025DERMJourney MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/13/2025DERMJourney MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.40M3.32N/AN/A$0.91 per share7.81GNFTGENFIT$67.00M3.14$0.07 per share59.90$1.50 per share2.80HRTXHeron Therapeutics$144.29M1.60N/AN/A($0.22) per share-5.73MAIAMAIA BiotechnologyN/AN/AN/AN/A$0.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.38N/AN/AN/A-15.49%-48.69%-11.26%11/11/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A9/22/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)MAIAMAIA Biotechnology-$23.25M-$1.38N/AN/AN/AN/A-497.29%-165.42%11/11/2025 (Estimated)Latest MAIA, GNFT, HRTX, and DERM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DERMJourney Medical-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.111.270.95GNFTGENFIT0.081.231.23HRTXHeron TherapeuticsN/A0.820.53MAIAMAIA BiotechnologyN/A2.192.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%GNFTGENFIT2.24%HRTXHeron Therapeutics80.01%MAIAMAIA Biotechnology5.65%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%GNFTGENFIT4.20%HRTXHeron Therapeutics5.86%MAIAMAIA Biotechnology32.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9026.31 million22.36 millionN/AGNFTGENFIT12050.00 million47.90 millionNot OptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableMAIAMAIA Biotechnology932.99 million22.33 millionNot OptionableMAIA, GNFT, HRTX, and DERM HeadlinesRecent News About These CompaniesMAIA Biotechnology Updates Business Presentation OnlineSeptember 13 at 2:46 AM | msn.comTHIO Plus Libtayo Elicits Positive Responses in Advanced NSCLCSeptember 12 at 6:14 PM | curetoday.comCMaia’s NSCLC immunotherapy secures Phase II efficacy winSeptember 12 at 6:14 PM | msn.comMAIA Biotechnology highlights efficacy data from THIO-101 Phase 2 trialSeptember 11 at 1:20 PM | msn.comMAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung CancerSeptember 11 at 1:20 PM | markets.businessinsider.comMAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung CancerSeptember 5, 2025 | globenewswire.comMAIA Biotechnology announces publication of interim clinical data on THIO-101August 28, 2025 | msn.comMAIA Biotechnology, Inc. Announces Publication of Phase 2 THIO-101 Clinical Trial Findings in Scientific Journal CellsAugust 27, 2025 | quiverquant.comQMAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal CellsAugust 27, 2025 | globenewswire.comMAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 3.3% - Here's What HappenedAugust 25, 2025 | marketbeat.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Large Increase in Short InterestAugust 21, 2025 | marketbeat.comDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)August 18, 2025 | globenewswire.comMAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer TherapyAugust 13, 2025 | manilatimes.netMMAIA Biotechnology granted European patent for telomere-targeting agentsAugust 13, 2025 | msn.comThe Targeted Pulse: FDA Designations, Access Gaps, and Strategic Advances in OncologyAugust 4, 2025 | targetedonc.comTMAIA Biotechnology receives US FDA fast track designation for ateganosine for the treatment of non-small cell lung cancerJuly 30, 2025 | pharmabiz.comPAteganosine Receives FDA Fast Track Designation for NSCLCJuly 29, 2025 | targetedonc.comTMaia Biotechnology shares jump after FDA awards Fast Track statusJuly 28, 2025 | msn.comMaia Biotechnology stock soars after FDA grants Fast Track designationJuly 28, 2025 | au.investing.comMAIA Biotechnology Receives FDA’s Fast Track Designation for AteganosineJuly 28, 2025 | contractpharma.comCMAIA Biotechnology Shares Rise After FDA Fast Track Designation for AteganosineJuly 28, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMAIA, GNFT, HRTX, and DERM Company DescriptionsJourney Medical NASDAQ:DERM$7.11 -0.24 (-3.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.14 +0.03 (+0.42%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.GENFIT NASDAQ:GNFT$4.20 +0.01 (+0.24%) As of 09/12/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Heron Therapeutics NASDAQ:HRTX$1.26 -0.02 (-1.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.29 +0.03 (+2.38%) As of 09/12/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.MAIA Biotechnology NYSEAMERICAN:MAIA$1.68 -0.02 (-1.18%) Closing price 09/12/2025 04:10 PM EasternExtended Trading$1.68 +0.01 (+0.30%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
